A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)

This is a multi-center, phase Ib/II trial to evaluate the safety and efficacy of CNCT19 treatment in Children and Adolescent (pediatric) patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-cell ALL).

Trial Details

NCT ID

NCT05667506

Phase

PHASE1 / PHASE2

Sponsor

Juventas Cell Therapy Ltd.

Status

RECRUITING

Cancer Type

Acute Lymphoblastic (ALL) Leukemia

Interventions

single dose of CNCT19

Locations (sample)

Hefei, Anhui, China|31.86389,117.28083
Chongqing, Chongqing Municipality, China|29.56026,106.55771
Guangzhou, Guangdong, China|23.11667,113.25
Guangzhou, Guangdong, China|23.11667,113.25
Wuhan, Hubei, China|30.58333,114.26667

Key Eligibility Criteria

Signed written informed consent prior to any study procedures (patient and/or parent or legal guardian)
Age 3 to 18. Weight ≥10kg
Relapsed or refractory acute lymphoblastic leukemia (ALL).
Documentation of CD19 tumor expression demonstrated in bone marrow or peripheral blood within 3 months before screening.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Acute Lymphoblastic (ALL) Leukemia Trials on Trialify →